Inventor
Minhua Chen
Inventor
Suzhou, CN
Overview
Patents· 35 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
C07Bprimary
C07BGeneral methods of organic chemistry24%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations23%
C07DHeterocyclic compounds23%
A61KPreparations for medical, dental or toiletry purposes20%
C07CAcyclic or carbocyclic compounds6%
B01DSeparation1%
C07HSugars1%
C07JSteroids1%
G01NInvestigating or analysing materials by determining their chemical or physical properties1%
PatentTitleYear
10,815,232Crystalline forms of viral-protein inhibitor drug VX-787, processes for preparation thereof and use thereof202010,815,221Crystal forms of an androgen receptor antagonist, preparation method and use thereof202010,759,779Crystalline form of orexin receptor antagonist, processes for preparation thereof and use thereof202010,752,595Crystalline forms of a bromodomain and extraterminal protein inhibitor drug, processes for preparation thereof, and use thereof202010,703,724Crystalline forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl] amino} acetic acid and processes for preparation thereof202010,633,376Crystalline forms of JAK1-selective inhibitor, processes for preparation and use thereof202010,626,135Crystal forms of sodium-glucose co-transporter inhibitor, processes for preparation and use thereof202010,604,521Crystalline forms of PLX3397 hydrochloride, processes for preparation and use thereof202010,604,528Galunisertib crystalline form, preparation method thereof and use thereof202010,577,334Crystalline form E of tafamidis meglumine, process for preparation and use thereof202010,577,372Galunisertib crystalline form, preparation method thereof and use thereof202010,562,855Crystalline form of lenvantinib mesylate and process of preparation thereof202010,544,129Crystalline forms of AP26113, and preparation method thereof202010,508,087Crystalline forms of trisodium supramolecular complex comprising valsartan and AHU-377 and methods thereof201910,487,064Crystalline forms of selective S1P1 receptor modulator and preparation method thereof201910,472,369Crystalline forms of (6-(1H-indazol-6-yl)-N-[4-(4-(4-morpholinyl)phenyl]imidazo[1,2-A]pyrazin-8-amine) methanesulfonate201910,442,775Preparation method for eutectic hydrate crystal form II of AHU-377 and diovan trisodium salt201910,442,800Crystal forms of NBI-98854, preparation method and use thereof201910,377,757Crystal form of JAK inhibitor and preparation method thereof201910,351,536Crystalline forms of lesinurad and its sodium salt201910,323,035Co-crystal of a CDK inhibitor and an MEK inhibitor and process of preparation thereof201910,308,641Crystal form of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxole-5-yl)cyclopropane formamido)-3-methylpyridine-2-yl)benzoic acid and preparation method thereof201910,273,262Crystalline form A of obeticholic acid and preparation method thereof201910,266,523Crystaline forms of N-[6-(cis-2,6-dimethylmorpholine-4-yl)pyridine-3-yl]-2-Methyl-4'-(trifluoromethoxy) [1,1'-biphenyl]-3-Methanamide monophosphate, and process of preparation thereof201910,246,437Crystal form of neratinib maleate and preparation method therefor201910,246,418Crystal form of lenvatinib methanesulfonate salt and preparation method thereof201910,233,144Crystalline form of AHU377, preparation method and use thereof201910,196,395Crystalline form alpha of IPI-145 and preparation method thereof201910,138,239Preparation method of crystalline form a of PCI-32765201810,138,250Salt of pyrrolo[2,3-D]pyrimidine compound and novel polymorph of salt20189,994,579Salt of pyrrolo[2,3-D]pyrimidine compound and novel polymorph of salt20189,969,701Salts and co-crystals of lesinurad20189,957,240Crystalline forms of trisodium supramolecular complex comprising valsartan and AHU-377 and methods thereof20189,751,889'Crystalline form I of ibrutinib'20178,674,105'Crystalline hydrochloride salts of c-Met kinase inhibitors'2014Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2014–2019Patents assigned to CHEN MINHUA (2)· patent assignee history
2014–2019Based in Scotch Plains, NJ, US· patent location history
2017–2019Patents assigned to SUZHOU PENGXU PHARMATECH CO LTD (5)· patent assignee history
2017–2018Patents assigned to CRYSTAL PHARMATECH INC (2)· patent assignee history
2018–2020Patents assigned to CRYSTAL PHARMATECH CO LTD (22)· patent assignee history
2018–2020Based in Suzhou, CN· patent location history
2018–2020Based in Jiangsu, CN· patent location history
2019–2020Patents assigned to CRYSTAL PHARMACEUTICAL SUZHOU CO LTD (9)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| CRYSTAL PHARMATECH CO LTD | 22 | 2018–2020 |
| CRYSTAL PHARMACEUTICAL SUZHOU CO LTD | 9 | 2019–2020 |
| SUZHOU PENGXU PHARMATECH CO LTD | 5 | 2017–2019 |
| CHEN MINHUAself | 2 | 2014–2019 |
| CRYSTAL PHARMATECH INC | 2 | 2017–2018 |
Locations
| Location | Patents | Span |
|---|---|---|
| Suzhou, CN | 16 | 2018–2020 |
| Jiangsu, CN | 13 | 2018–2020 |
| Scotch Plains, New Jersey, US | 6 | 2014–2019 |